Creative Biolabs provides comprehensive, end-to-end antibody and peptide discovery services for research programs concerning treatment and diagnosis of parasitic diseases, covering Leishmania, Brugia, and Plasmodium.
New York, United States - December 13, 2021 /MarketersMEDIA/ —
Parasitic infections are ubiquitous in wildlife, livestock, and human populations, and healthy ecosystems are often parasite-rich. Yet, their negative impacts can be extreme as parasitic infections have been a big problem especially in tropical and subtropical regions of the world. Research has proved that antibodies and novel peptide molecules have the potential to be new pharmaceutical products for the treatment or diagnosis of parasite diseases.
With the high-quality, end-to-end CRO services supported by a highly experienced team, Creative Biolabs is dedicated to sharing cutting-edge technology and extensive expertise in antibody and peptide discovery for parasitic diseases, and providing related services to facilitate clients' research and project development, concerning Leishmania, Brugia, Plasmodium, Neospora, Cryptosporidium, Eimeria, Fasciola, Schistosoma, Toxoplasma, Strongyloides, Taenia, Trypanosoma, etc.
· Discovery of Biomolecule Targeting Leishmania
Scientists at Creative Biolabs keep up with the new research on anti-Leishmania biomolecular discovery research and are skillful in one-stop services about related targets for antibody and peptide drug development, covering promising targets such as kinetoplastid membrane protein-11, glycoprotein 63, Leishmania homologue of receptor for activated C kinase (LACK), fucosemannose ligand (FML), and LCR1 protein.
· Discovery of Biomolecule Targeting Brugia
Creative Biolabs offers comprehensive anti-Brugia biomolecule development services on abundant larval transcript-2 (ALT-2), which functions a major role in the transmission and infectivity of the filarial parasite, and Brugia malayi heat shock protein 12.6 (BmHsp12.6), which is shown in previous research to exert significant protection in mice model.
· Discovery of Biomolecule Targeting Plasmodium
Supported by the advanced AntInfectTM Platform developed especially to optimize neutralizing antibody generation, Creative Biolabs launches custom anti-Plasmodium biomolecular generation services focusing on helping researchers find novel antibody or peptide drugs. The expert team is proficient at research on known targets, inclusive of apical membrane antigen 1 (AMA1), erythrocyte binding antigen-175 (EBA-175), and P. falciparum reticulocyte binding protein homologue 5 (PfRH5).
In addition to the aforementioned targets, the team of seasoned scientists is also confident in processing novel targets to accelerate the innovative programs of clients.
“Antimicrobial peptides and antibodies have been hypothesized as a possible alternative to conventional drugs because of less occurrence of resistance, broad-spectrum activity, and generally low toxicity. We utilize phage display and high-density peptide array technologies to offer high-throughput and high-quality specific peptide discovery services,” as introduced by a senior scientist at Creative Biolabs, “and for antibody discovery, we can tailor strategies for different targets, and guarantee to generate anti-parasite antibodies with high specificity and stability.”
More information about antibody/peptide discovery services for other parasitic diseases at Creative Biolabs can be found at https://www.creative-biolabs.com/antinfect/.
About Creative Biolabs
As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technologies to support functional biomolecule development for infectious diseases. The service portfolio is comprised of anti-infective antibody and peptide discovery and small molecule drug discovery for a wide range of virus, bacterium, and parasite infection.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/antinfect/
Source: MarketersMEDIA
Release ID: 89056270
